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Recent evidence suggests that comorbidities between neuropsychiatric conditions and metabolic 
syndrome may precede and even exacerbate long-term side-effects of psychiatric medication, such as 
a higher risk of type 2 diabetes and cardiovascular disease, which result in increased mortality. In the 
present study we compare the expression of key metabolic proteins, including the insulin receptor 
(CD220), glucose transporter 1 (GLUT-1) and fatty acid translocase (CD36), on peripheral blood 
mononuclear cell subtypes from patients across the neuropsychiatric spectrum, including 
schizophrenia, bipolar disorder, major depression and autism spectrum conditions (n=25/condition), 
relative to typical controls (n=100). This revealed alterations in the expression of these proteins that 
were specific to schizophrenia. Further characterization of metabolic alterations in an extended cohort 
of first-onset antipsychotic drug-naïve schizophrenia patients (n=58) and controls (n=63) revealed that 
the relationship between insulin receptor expression in monocytes and physiological insulin sensitivity 
was disrupted in schizophrenia and that altered expression of the insulin receptor was associated with 
whole genome polygenic risk scores for schizophrenia. Finally, longitudinal follow-up of the 
schizophrenia patients over the course of antipsychotic drug treatment revealed that peripheral 
metabolic markers predicted changes in psychopathology and the principal side effect of weight gain 
at clinically relevant time points. These findings suggest that peripheral blood cells can provide an 
accessible surrogate model for metabolic alterations in schizophrenia and have the potential to 
stratify subgroups of patients with different clinical outcomes or a greater risk of developing metabolic 
complications following antipsychotic therapy.
Keywords
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1. Introduction
Major neuropsychiatric conditions represent a significant burden on worldwide health, 
accounting for 31% of years lived with disability (YLD) and a lifetime prevalence of over 20% 
of the global population (approximately 2.4% for bipolar disorder (BD), 1-2% for schizophrenia 
(SCZ) and autism spectrum conditions (ASC) and 17% for major depressive disorder (MDD), 
depending on geographic region1–7). They are associated with substantial comorbidities 
including suicide, cardiovascular diseases, immune disorders, metabolic syndrome and 
substance abuse5,8,9. Current treatments are effective in only 40-60% of individuals10–14 with 
potential debilitating side effects, such as extrapyramidal symptoms, weight gain and over-
sedation, in addition to treatment refractory symptoms, such as negative and cognitive 
symptoms, being persistent problems15,16. A fundamental lack of understanding about 
neuropsychiatric pathophysiology and the interaction between genetic17 and environmental 
risk factors, limited characterization of the mechanisms of existing drugs and a paucity of 
relevant preclinical models have significantly impeded progress towards improved therapies. 
Moreover, neuropsychiatric heterogeneity and diagnostic instability have emphasized the 
need to identify readily accessible biomarkers which are capable of stratifying patient 
populations and predicting clinical response to treatment18,19.
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In recent years a considerable body of evidence has indicated the association of metabolic 
disturbances with neuropsychiatric conditions. For example, metabolic syndrome, which 
comprises visceral adiposity, insulin resistance, hyperglycemia, increased triglycerides, 
reduced high density lipoprotein (HDL) cholesterol and elevated blood pressure, is prevalent 
in people with SCZ and is thought to contribute to an increased risk of premature mortality 
due to cardiovascular disease and type 2 diabetes9. Relative to the general population, people 
with SCZ die on average 15-30 years earlier, largely as a result of cardiovascular complications, 
and show a 2-3 fold increased prevalence of type 2 diabetes20. While metabolic abnormalities 
have received most attention in SCZ, a recent metanalysis of 198 studies including 52,678 
participants with a severe mental illness suggested that the risk of metabolic syndrome may 
be similarly elevated in individuals with other major neuropsychiatric conditions such as BD 
and MDD21. In the past, these risks have been largely attributed to side effects of specific 
neuropsychiatric medications, such as the atypical antipsychotics clozapine and olanzapine21, 
and the high prevalence of smoking among patients22,23. However, recent data suggests that 
there might be a predisposition to metabolic abnormalities in subgroups of patients which 
precedes the onset of pharmacological treatment or extended illness duration24–27. In the 
case of SCZ, evidence includes reports of elevated circulating insulin and insulin-related 
peptides27,28, impaired glucose tolerance22, hepatic insulin resistance22, hyperlipidaemia23 
and abnormal glucose metabolism in the brain and peripheral tissues26,29. Importantly, 
subsets of these metabolic abnormalities have also been reported in unaffected siblings of 
SCZ patients relative to controls24, identified through largescale meta-analyses of glucose 
homeostasis in drug-naïve patients at disease onset20 and associated with polygenic risk of 
SCZ30, suggesting that they might represent a pre-existing risk factor which is linked to the 
biological aetiology of the disease. While investigations into putative metabolic disturbances 
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in other neuropsychiatric conditions are more limited31–35, shared heritability and significant 
overlap of genetic risk loci and biological pathways36,37 between major neuropsychiatric 
conditions suggests that common metabolic alterations are plausible. This is highlighted by 
the enrichment of genetic risk loci in gene sets related to insulin secretion in the largest 
genome-wide association study of BD to date38, evidence of mitochondrial dysfunction in 
ASC32 and reports of hyperglycemia and hypertriglyceridemia in MDD33.
At the same time alterations in the immune system have been reported across several 
neuropsychiatric conditions. These include pro-inflammatory cytokine alterations in first-
episode drug-naïve MDD and SCZ patients39–41, differences in the relative proportions and 
activation profile of circulating peripheral blood mononuclear cells (PBMCs) in SCZ and ASC42–
45, activation of brain microglia suggested by post-mortem immunohistochemistry and in vivo 
positron emission tomography (PET) studies in ASC and SCZ46–48 and enrichment of genetic 
risk loci in genomic regions which are key to immunological function (e.g. major 
histocompatibility complex (MHC) region and B cell subtype-specific gene expression 
enhancers in SCZ49). Moreover subsets of these immune alterations appear to be linked to 
active symptomatology (e.g. interleukin (IL)-6 and tumour necrosis factor- in MDD50 and IL-
6, IL-1 and transforming growth factor- in SCZ51), disease severity (e.g. GSK-3 
phosphorylation in PBMCs in BD52) and putative aetiological stages in disease progression 
(e.g. synaptic pruning during postnatal development proposed for SCZ53 and ASC54). These 
changes might have implications also for the central nervous system (CNS), as expression of 
subsets of genes in whole blood correlates with gene expression in multiple brain regions55.
Although the direction of causality between these immune and metabolic alterations and 
psychiatric symptomatology in the CNS is widely debated56, it is likely that such alterations 
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characterize subgroups of patients with distinct prognostic features25. For example, in SCZ 
elevated peripheral cytokines (IL-1β, IL-18, IL-8 and IL-2) have been suggested to characterize 
a subgroup of patients with treatment refractory symptoms, such as cognitive deficits57, while 
oxidized low density lipoprotein receptor expression and peripheral insulin resistance have 
been shown to predict clinical response to antipsychotic treatment in drug-naïve patients30,58. 
Likewise, in MDD baseline peripheral IL-8 levels59 and plasma concentrations of high-
sensitivity C-reactive protein60 have been associated with antidepressant or adjunctive 
therapy responses, respectively, while in BD features of metabolic syndrome have been 
associated with adverse clinical outcomes such as treatment resistance, rapid cycling and 
progression to chronic illness34. Finally, in addition to associations with treatment response, 
metabolic and immune markers have shown the potential to predict side-effects of 
treatment, notably weight gain and metabolic syndrome following second-generation 
antipsychotic administration in SCZ61–64.
In the present study we integrate biological markers of immunity and metabolism by 
measuring the cell-surface expression of key mediators of metabolic homeostasis, glucose 
transporter 1 (GLUT1), insulin receptor (IR) and fatty acid translocase (CD36), on abundant 
PBMC subtypes (CD4+ T cells, CD8+ T cells, CD4-/CD8- T cells, B cells and monocytes) from 
peripheral blood samples of neuropsychiatric patients and controls. The criteria for selection 
of these metabolic markers involved: 1) direct implication in metabolic syndrome65–69, 2) 
significant basal expression in subtypes of PBMCs and CNS cells, 3) previous associations to 
neuropsychiatric disease26,70–76 and 4) availability of reproducible monoclonal antibodies 
validated for use in flow cytometry. First, we use this information to identify which major 
neuropsychiatric conditions, including ASC, BD, MDD and SCZ, are most likely to exhibit 
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peripheral metabolic abnormalities in PBMCs. Subsequently, we characterize these 
abnormalities in relation to systemic indicators of metabolic syndrome, such as altered insulin 
sensitivity and glucose homeostasis, in addition to polygenic disease risk in drug-naïve patient 
samples. Finally, we assess the clinical relevance of PBMC metabolic markers for predicting 
early response to treatment or side effects, such as weight gain, in relevant conditions with a 
longitudinal clinical follow-up of up to 3 years.
2. Materials and methods
2.1 Clinical sample recruitment
Patients and matched typical control PBMC donors across the neuropsychiatric spectrum (NS 
study) were recruited as follows: autism spectrum condition (ASC; Cambridge Autism 
Research Centre, Cambridge University, Cambridge, UK; n=25/group), bipolar disorder (BD; 
Foundation Biological Psychiatry, Sofia, Bulgaria; n=13 patients and n=15 controls; and Union 
House, Cambridgeshire and Peterborough Mental Health Foundation Trust, Cambridge, UK; 
n=12 patients and 10 controls), major depressive disorder (MDD; Westfälische Wilhelms 
University Hospital, Münster, Germany; n=25/group) and first-onset antipsychotic drug-naïve 
schizophrenia (SCZ; University Hospital Marqués de Valdecilla, Santander, Spain; n=25/group; 
Tables S1 and S2). In the BD cohort, patients and respective controls from different clinical 
centers were matched within and between centers for age, sex and body mass index (BMI). 
For the extended SCZ (ES study) cohort, PBMCs from first-onset antipsychotic drug-naïve SCZ 
PBMC samples (n=34) and matched controls (n=39) were collected at the University Hospital 
Marqués de Valdecilla, Santander, Spain, and combined for analysis with the aforementioned 
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SCZ cohort (total SCZ n= 58 and Ctrl n=63 after excluding two samples with low cell viability 
(<50%) from the analysis; Table S3). Control as well as SCZ groups were matched between the 
two SCZ cohorts for age, sex and BMI (P>0.05). The medical faculty ethical committees 
responsible for the respective sample collection sites approved the study protocols. Informed 
consent was given in writing by all participants and clinical investigations were conducted 
according to the Declaration of Helsinki 77 and Standards for Reporting of Diagnostic 
Accuracy78.
Diagnoses of neuropsychiatric pathology were conducted by experienced psychiatrists and 
were based on the Diagnostic and Statistical Manual of Mental Disorders-IV-Text Review 
(DSM-IV-TR)79. The severity of symptoms in SCZ was measured using the Brief Psychiatric 
Rating Scale (BPRS)80, the Scale for the Assessment of Positive Symptoms (SAPS) and the Scale 
for the Assessment of Negative Symptoms (SANS)81. Measurements of serum biochemistry, 
including cholesterol, high-density lipoprotein, low-density lipoprotein, glucose, insulin and 
triglycerides, and body mass index (BMI) were conducted as part of the routine clinical follow-
up. Follow-up data was collected at baseline, 3 weeks, 6 weeks, 3 months, 1 year and 3 years 
for BPRS, SAPS and SANS and at baseline, 3 months, 1 year and 3 years for BMI and serum 
biochemistry measurements. The exclusion criteria for patients and controls included: age 
below 18 years old, additional neuropsychiatric diagnoses, other neurological conditions 
including epilepsy, mental retardation, multiple sclerosis, immune/autoimmune conditions, 
infectious disease, metabolic conditions including diabetes, obesity, cardiovascular disease, 
hepatic and renal insufficiency, gastrointestinal conditions, endocrine conditions including 
hypo-/hyperthyroidism and hypo-/hypercortisolism, respiratory diseases, cancer, severe 
trauma, substance abuse including psychotropic drugs and alcohol, somatic medication for 
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non-CNS indications with CNS side-effects and somatic medication affecting the immune 
system including glucocorticoids, anti-inflammatory/immuno-modulating drugs and 
antibiotics.
2.2 PBMC isolation and culture
PBMCs were prepared within 4 hours from blood collected into 7.5 ml sodium heparin tubes 
(BD Biosciences; ASC, BD and MDD) or acid citrate dextrose solution A tubes (BD Biosciences; 
SCZ). Whole blood was pelleted at 500 g for 10 min to remove platelet-rich plasma, diluted 
1:1 with Dulbecco’s phosphate-buffered saline solution (PBS; Sigma-Aldrich) and centrifuged 
over Ficoll-Paque PLUS (GE Healthcare) at 750 g for 20 min at 23oC (15 min at 1000 g for BD 
samples from Sofia). PBMCs were extracted from the interphase, washed three times with 
PBS at 300 g for 10 min (once at 760 g for 10 min for BD samples from Sofia) and cryopreserved 
at 5*106 cells/ml in heat-inactivated fetal bovine serum (FBS; Sigma-Aldrich) (Roswell Park 
Memorial Institute (RPMI)-1640 medium with 25 mM Hepes, Ultraglutamin-1, 10% FBS and 
1% penicillin-streptomycin for BD samples from Sofia) containing 10% dimethyl sulfoxide 
(DMSO; Sigma-Aldrich). PBMCs were thawed at 37oC and resuspended in sterile conditions in 
complete RPMI media with deoxyribonuclease (DNAse) (RPMI-1640 with sodium bicarbonate 
(Sigma-Aldrich), 10% FBS (Life Technologies), 50 U/ml penicillin and 50 µg/ml streptomycin 
(Life Technologies), 2 mM L-alanyl-L-glutamine dipeptide (Life Technologies) and 20 µg/ml 
DNAse (Sigma-Aldrich)). The cells were counted using a Coulter Counter (Beckman Coulter), 
pelleted, resuspended at 1*106 cells/ml in FACS buffer (PBS with 0.5% bovine serum albumin 
(Sigma-Aldrich)), strained via a 40 µm cell strainer (Corning) and distributed into in 96-well 
polypropylene plates (Starlab). Samples from participants from different clinical groups 
(n=200; NS) and (n=73; ES), alongside quality control (QC) samples (n=16; NS) and (n=10; ES) 
Descargado para Anonymous User (n/a) en IDIVAL, de ClinicalKey.es por Elsevier en septiembre 10, 2020.
Para uso personal exclusivamente. No se permiten otros usos sin autorización. Copyright ©2020. Elsevier Inc. Todos los derechos reservados.
11
from a single typical control donor, were randomized across different plate positions and 
experimental days to minimize measurement-related batch effects.
2.3 Staining for metabolic markers, immunophenotyping and cell viability
PBMCs were resuspended at 1*106 cells/ml in FACS buffer with 20% human Fc receptor 
binding inhibitor (eBioscience) and incubated for 20 min at room temperature (rtp) in 96-well 
polypropylene plates (Starlab). The PBMCs were stained in a total volume of 135 µl/tube with 
0.5 µl of anti-human CD3 (UCHT1) PE-Cy7 (eBioscience), 0.5 µl of anti-human CD4 (SK3) PerCP-
eFluor 710 (eBioscience), 0.5 µl of anti-human CD8 (SK1) APC-eFluor 780 (eBioscience) and 
0.3 µl of anti-human CD14 (MφP9) V500 (BD Biosciences). Additionally, 10 µl of anti-human 
GLUT1 (202915) FITC, 20 µl of anti-human CD220 (IR) (3B6/IR) PE and 2.5 µl of anti-human 
CD36 (NL07) eFluor660 was added to wells stained with metabolic markers as per 
manufactures instructions, while an equivalent volume of FACS buffer was added to 
unstained control wells per sample. The cells were incubated in the dark for 30 min at room 
temperature. They were washed twice with 200 µl of FACS buffer, resuspended in 200 µl of 
FACS buffer with 1 µM DAPI (Sigma-Aldrich) and stored at 4oC until acquisition.
2.4 Data acquisition using flow cytometry
PBMC cell suspensions were acquired using an eight color FACSVerse flow cytometer (BD 
Biosciences) with 405, 488 and 640 nm laser excitation at an average flow rate of 2 µl/sec and 
an average threshold event rate of 1,000-2,000 events/sec. Multicolor Cytometer Setup and 
Tracking beads (BD Biosciences) were used for quality control and standardization of 
photomultiplier tube detector voltages across multiple experimental runs. Fluorescence 
compensation was conducted using anti-mouse IgG antibody capture beads (Bangs 
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Laboratories) labelled separately with anti-human CD3 (UCHT1) PE-Cy7, anti-human CD4 
(SK3) PerCP-eFluor 710,  anti-human CD8 (SK1) APC-eFluor 780, anti-human CD14 (MφP9) 
V500 (BD Biosciences), anti-human GLUT1 (202915) FITC, anti-human CD220 (IR) (3B6/IR) PE 
and anti-human CD36 (NL07) eFluor660, alongside single stain controls with DAPI.
2.5 Genotype analysis and calculation of polygenic risk scores
All patients were genotyped using the Illumina Infinium PsychArray Bead Chip and imputed 
using the standard SHAPEIT2/IMPUTE2 pipeline. PLINK 1.9 was used for the calculation of 
Polygenic Risk Scores (PRS) using methodologies described elsewhere82. Briefly, based on the 
results of the SCZ-PGC GWAS49 and using a P-value threshold= 1, PRS were calculated 
multiplying the imputation dosage for each risk allele by the effect size for each genetic 
variant. A total number of 113,282 independent variants were included. The resulting values 
were summed up in an additive fashion obtaining an individual estimate of the genetic load 
for schizophrenia risk in each subject.
2.6 Genotype-Tissue Expression dataset
The Genotype-Tissue Expression (GTEx) project data83 were used to investigate the 
correlation in gene expression of the selected markers between peripheral blood/Epstein-
Barr virus (EBV)-transformed lymphocytes and 12 brain regions. Gene expression data 
(GTEx_Analysis_2017-06-05_v8_RNASeQCv1.1.9_gene_tpm) were downloaded from 
https://gtexportal.org/home/datasets and matched within donors using the 
GTEx_Analysis_v8_Annotations_SampleAttributesDS sample information file. Only CD36, 
INSR (insulin receptor) and SLC2A1 (GLUT1) gene expression data were analysed.
2.7 Statistical data analysis
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Flow cytometry data was analyzed in FCS 3.0 file format using Flow Jo v.10.0.8 software (Tree 
Star). Statistical analysis was conducted using R v.3.6.1 software (R Core Team)84. PBMC 
samples in which the lymphocyte gate contained less than 60% of events, measured by 
forward scatter (FSC-A)/side scatter (SSC-A), were excluded from further analysis. 
Experimental variables including positional effects within and across 96-well plates, sample 
viability, cell counts, experimental day, clinical group and sample source were investigated 
using principal component analysis. Batch effects in median fluorescence intensities (MFIs) 
caused by running samples from different clinical centres (NS) or different experimental runs 
(ES) were normalized for each metabolic marker and PBMC subtype using median scaling 
based on control samples from each clinical centre (NS) or experimental run (ES). Matching 
of clinical groups was conducted using the Wilcoxon rank-sum test (Kruskal-Wallis test for 
more than two groups) for continuous variables or the Fisher’s exact test (chi-squared test for 
more than two groups) for categorical variables. All statistical tests were two-sided, unless 
specified otherwise. P values were adjusted for multiple comparisons using the Benjamini-
Hochberg procedure (shown as Q values). Samples with missing data were excluded from 
analysis.
The stain index of each antibody, per PBMC subtype, was calculated across PBMC samples for 
each study and clinical group individually as the median MFI of the antibody-stained sample 
divided by the median MFI of the corresponding unstained control. For comparison of 
metabolic marker expression across clinical groups, only metabolic markers with a median 
stain index greater than two in at least one of the comparison groups were used for analysis. 
Likewise, for each PBMC cell subtype only samples with a minimum of 100 live cells in the 
PBMC cell subtype gate were included in analysis. Control data from the NS study were 
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combined across the cohorts to increase statistical power and allow more direct group 
comparisons. Association of metabolic marker expression in each PBMC subset with clinical 
group status was investigated using the analysis of covariance (ANCOVA) F-test (P<0.05) after 
adjusting for covariates. Optional covariates, age, sex, BMI, treatment status (NS) and cell 
counts, were selected in a stepwise procedure for each marker and PBMC subtype separately 
using Bayesian Information Criterion.  Pairwise t-test comparisons of adjusted group means 
were used to determine which clinical groups differed significantly from typical controls 
(P<0.05).  Additionally, a threshold fold change of at least 5% in either direction for at least 
one clinically significant group relative to controls was used to define metabolic markers and 
PBMC subsets with significantly altered expression. Box plots of disease-associated nodes 
show interquartile range with the median (horizontal line) and the minimum and maximum 
values (whiskers), excluding outliers (dots). 
For follow-up analyses in the ES cohort, the updated Homeostasis Model Assessment 
(HOMA2)85 was used to infer IR, β cell function, and insulin sensitivity from clinical 
measurements of fasting serum glucose and insulin levels. Associations of metabolic markers, 
significantly linked to SCZ in the ES cohort, with HOMA-2 metrics, SCZ polygenic risk score 
(PRS) and clinical measures of symptom improvement (BPRS, SAPS and SANS) or side 
effects (BMI, cholesterol, HDL, LDL, glucose, insulin and triglycerides) were 
investigated using multivariable linear regression. Changes in symptoms or side effects were 
calculated as scores at follow-up time point – scores at baseline (0 weeks) time point. For 
HOMA-2 and PRS analyses, the predictive variables of clinical group and HOMA2 or PRS were 
set as interaction terms, alongside main effect terms, within the model to determine whether 
the relationship between metabolic marker expression and HOMA-2 or PRS differed across 
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the clinical groups (P<0.05). Optional covariates, age, sex, BMI and cell counts, in addition to 
baseline measures (BPRS, SAPS, SANS, BMI, cholesterol, HDL, LDL, glucose, insulin and 
triglycerides), GWAS principal components 1 to 4 for PRS analysis (to account for ancestry), 
and treatment drug when predicting response to treatment, were selected in a stepwise 
procedure for each marker and PBMC subtype separately using Bayesian Information 
Criterion. 
Correlation in gene expression between peripheral blood/EBV-transformed lymphocytes and 
12 brain regions in the GTEx project data was analysed using one-tailed Spearman’s rank-
order correlation (H0: ρ≤0; H1: ρ>0).




3.1 Expression of metabolic markers across neuropsychiatric spectrum
To explore peripheral markers of metabolic abnormalities across the neuropsychiatric 
spectrum, we compared the cell surface expression of GLUT1, IR and CD36 proteins on 
different PBMC subtypes, including CD4+ T cells, CD8+ T cells, CD4-/CD8- T cells, CD3- cells 
(largely B and natural killer (NK) cells; labelled 'B cells') and monocytes, from individuals with 
autism spectrum condition (ASC), bipolar disorder (BD), major depressive disorder (MDD) and 
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schizophrenia (SCZ) (n=25 each) relative to typical controls (Ctrl; n=100; Fig. S1 and S2; Table 
S1 and S2). In addition to previously reported differences in the relative frequencies of 
immune cell subsets in specific neuropsychiatric conditions (Fig. S3), the data revealed that 
significant (ANCOVA P<0.05, fold change >5%) alterations in the expression of these metabolic 
markers were associated solely with SCZ. These included altered expression of CD36 in CD4+ 
(adjusted fold change (FC)=1.46) and CD4-/CD8- (FC=1.29) T cells and GLUT1 in monocytes 
(FC=0.74) and CD8+ T cells (FC=1.06; Fig. 1; Table S4).
3.2 Characterization of metabolic alterations in schizophrenia
To further investigate the metabolic abnormalities observed in SCZ, we assessed the same 
cell surface markers in PBMC subsets from an extended cohort of first-onset antipsychotic 
drug-naïve SCZ patients and controls (Fig. S4 and S5 and Table S3). This revealed significant 
(ANCOVA P<0.05, fold change >5%) alterations in the expression of CD36 in CD4+ (FC=1.64) 
and CD4-/CD8- (FC=1.22) T cells and GLUT1 (FC=0.68) and IR (FC=1.11) in monocytes 
associated with SCZ (Fig. 2; Table S5). Given the relevance of these markers to metabolic 
homeostasis, we investigated their relationship to key indicators of metabolic syndrome, 
including insulin sensitivity, insulin resistance and pancreatic -cell function calculated using 
the Homeostasis Model Assessment (HOMA2) tool and fasting measures of serum glucose 
and insulin concentration across the clinical groups. This revealed that the expression of IR in 
monocytes was significantly associated with HOMA2 insulin sensitivity in the control group 
(β=0.45, P=0.005), but not the SCZ group (β=0.16, P=0.36; Fig. 3a; Table S6). We furthermore 
explored whether altered expression of metabolic markers in PBMCs was associated with 
whole-genome polygenic risk of SCZ across the clinical groups. This showed that the 
relationship between SCZ polygenic risk score and IR expression in monocytes differs 
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significantly (interaction P=0.027) between the SCZ (β=19.5) and control (β=-20.1) groups (Fig. 
3b; Table S7).
3.3 Prediction of clinical response and side effects in schizophrenia
To assess the clinical relevance of PBMC metabolic markers which were altered in SCZ, we 
explored their potential to predict early response to antipsychotic treatment, defined as 
changes in the Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment of Positive 
Symptoms (SAPS) and Scale for the Assessment of Negative Symptoms (SANS) scores at 6 
weeks and 3 months, in addition to the principal side-effect of weight gain, defined by 
changes in body mass index (BMI) at 3 months, through longitudinal clinical follow-up of the 
drug-naïve SCZ cohort (Fig. S6). This revealed that baseline IR expression in monocytes 
predicted improvement in general psychopathology (BPRS; β6weeks=-0.031, P6weeks=0.007; 
β3months=-0.023, P3months=0.039; Fig. 4a,b; Table S8) and negative symptoms of SCZ (SANS; 
β6weeks=-0.017, P6weeks=0.017; β3months=-0.016, P3months=0.028; Fig. 4c,d; Table S8) at clinically 
relevant time points early in the treatment course, six weeks and three months. Moreover, 
CD36 expression in CD4+ T cells predicted the side-effect of increased BMI at three months 
(BMI; β=0.015, P=0.005; Fig. 4e; Table S8). Consistent with weight gain, the cohort also 
displayed long-term indicators of metabolic syndrome (up to 3 years) such as increased serum 
glucose, triglycerides, cholesterol, LDL and decreased HDL. Exploratory analysis of other 
PBMC cell types which strongly express CD36 (stain index>10) showed that CD36 expression 
in monocytes additionally predicted changes in BMI (BMI; β=5.4x10-5, P=0.035) and HDL 
(HDL; β= -0.0004, P= 0.046) at three months.
3.4 Gene expression correlation between blood and brain
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Exploratory correlation of CD36, INSR (IR) and SLC2A1 (GLUT1) gene expression in whole 
blood and EBV-transformed lymphocytes with gene expression in 12 brain regions using GTEx 
project data based on independent samples from the GTEx database showed that gene 
expression of CD36 in peripheral whole blood significantly correlated with CD36 expression 
in the frontal cortex (Brodmann area 9; N=159, ρ=0.22, P=0.003), amygdala (N=109, ρ=0.19, 
P=0.024), caudate (N=186, ρ=0.13, P=0.035) and cerebellum (N=193, ρ=0.12, P=0.050), in 
addition to significant correlation in CD36 expression between EBV-transformed lymphocytes 
and nucleus accumbens (N=22, ρ=0.37, P=0.046). No other significant correlations were 
observed.
4. Discussion
The present findings extend a growing body of evidence that peripheral metabolic alterations 
are a feature of SCZ even before the administration of antipsychotic drugs with known 
metabolic side effects20,25–27. However, while the majority of studies have focused on 
alterations of secreted metabolic factors such as insulin and insulin-related peptides, the 
present study suggests that circulating immune cells also bear the imprint of metabolic 
alterations in the form of abnormal cell surface protein expression of key metabolic 
regulators, such as GLUT1, IR and CD36. 
Interestingly, metabolic abnormalities were only observed in SCZ patient-derived PBMCs and 
not in PBMCs from patients with other major neuropsychiatric conditions. This is notable 
given recent reports of genetic overlap and bidirectional epidemiological associations 
between mood disorders and cardiometabolic diseases21,86. Potential explanations for this 
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discrepancy include that fact that many shared risk genes (e.g. CACNB2, GSK3B and CREB1) 
are highly pleiotropic86 with incompletely characterized functions or lack of phenotypic 
specificity in the context of polygenic conditions. It could also be that the shared genetic 
variants in these conditions impact metabolism by indirect means such as altering circadian 
rhythms and abnormal hypothalamic-pituitary-adrenal axis function86 and these changes are 
not reflected as metabolic abnormalities in blood cells, at least for the proteins measured. A 
final consideration is that putative metabolic alterations in mood disorders may be more 
indicative of ‘disease state’ rather than ‘disease trait’, as suggested by differential GLUT1 
methylation patterns in blood collected from acute versus remitted patients with MDD72,87. 
Given that the SCZ patients in the present study were all drug-naïve while the other cohorts 
had mixed medication status, this finding requires further exploration in wider drug-naïve 
patient populations. These results suggest that while metabolic and immune abnormalities 
might be a feature of other neuropsychiatric conditions, the interaction between the two 
features is likely to be more prominent in SCZ. However further testing is required across the 
neuropsychiatric spectrum using other key metabolic markers, beyond those tested in the 
present study, to confirm this hypothesis.
The increased expression of IR and CD36 and decreased expression of GLUT isoforms in PBMC 
subsets in SCZ is consistent with alterations in the expression of these proteins in tissue types 
linked with insulin resistance, such as adipose and muscle tissue, in metabolic 
syndrome66,68,88–90. In this respect, increased IR expression in monocytes in SCZ might reflect 
a compensatory response to decreased peripheral IR sensitivity. This is supported by the 
finding that the relationship between IR expression and insulin sensitivity (HOMA2-%S) is 
disrupted in SCZ relative to controls in the present study. Likewise, decreased expression of 
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GLUT1 in monocytes is consistent with impaired glucose uptake and increased circulating 
glucose concentrations observed in both metabolic syndrome and SCZ9,20,66,68,88. Although 
GLUT1 is not considered to be directly regulated by IR, as is the case for GLUT4, its high affinity 
for glucose and widespread expression mean that it is vital for the constitutive uptake of 
glucose into a range of tissues. Notably, GLUT1 is the principal glucose transporter in the 
blood-brain barrier and, in addition to GLUT3, one of the main glucose transporters in the 
brain71,73. The current results align with previous findings suggesting that deficits in brain 
glucose uptake and energy metabolism could represent pathophysiological features of SCZ. 
These include decreased GLUT1 and GLUT3 mRNA expression in pyramidal neurons and 
decreased activity of key glycolytic enzymes, hexokinase and phosphofructokinase, in the 
dorsolateral prefrontal cortex of individuals with SCZ post mortem91, decreased availability of 
brain high-energy phosphates in drug-naïve SCZ patients in vivo92 and subsets of SCZ-like 
behavioural symptoms in GLUT knockout mice74. Specifically, these alterations have been 
proposed to participate in the aetiology of SCZ by altering synaptic pruning and affecting 
neurotransmission through glutamine-glutamate cycling and are suggested to contribute to 
treatment resistant symptoms such as cognitive deficits74,93. Interestingly, GLUT1 showed 
increased expression in CD8+ T cells in the cross-disorder study although this finding did not 
replicate in the extended SCZ cohort. This indicates that the GLUT1 expression may be subject 
to cell subtype-specific dysregulation at least in subgroups of patients. This hypothesis 
warrants further investigation in larger patient cohorts.  Taken together, the present findings 
suggest that GLUT1 expression in monocytes might provide an accessible surrogate model for 
investigating systemic abnormalities in glucoregulatory pathways including the brain.
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Increased expression of CD36 in CD4+ and CD4-CD8-  T cells in SCZ is consistent with 
upregulation of CD36 in human and animal models of insulin resistance90. In fact, permanent 
relocation of CD36 in muscle and adipose tissue is considered an early event in the 
development of metabolic syndrome, with subsequent accumulation of intracellular fatty 
acids contributing to increased lipid storage, inhibition of insulin signalling by fatty acid 
metabolites, such as diacylglyceroles and ceramides, and reduced insulin-sensitive GLUT4 
expression90. Interestingly, studies involving CD36 knock-out or knock-in animal models and 
human subjects with CD36 genetic variants suggest that both ablation and up-regulation of 
CD36 can result in insulin resistance depending on the context and tissue type affected65. 
CD36 also has a range of other functions serving as a receptor for thrombospondin-1, 
scavenging oxidized phospholipids and LDL, recognizing bacterial and fungal pathogens and 
participating in sensory perception65. Importantly, the binding of oxidized LDL by CD36 on 
platelets and macrophages contributes to platelet activation and the formation of 
atherosclerotic plaques resulting in a prothrombotic state, while the binding of 
thrombospondin-1 to CD36 on endothelial cells regulates angiogenesis65,94. These features 
are particularly relevant to SCZ, given the increased risk of cardiovascular disease. 
Interestingly, CD36 has also been found to regulate astrocyte activation in the brain 
suggesting that its effect may also extend to the CNS95. The potential relevance of our findings 
for the CNS is further supported by the observation that expression of CD36 in peripheral 
blood and EBV-transformed lymphocytes correlated with CD36 expression in multiple brain 
regions in the GTEx dataset. Taken together, this data suggests that further studies are 
required to explore the role of CD36 in SCZ including tissue-specific alterations in expression 
and their potential functional role in comorbidities such as cardiovascular and insulin 
resistance.
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Given the close functional relationship and reciprocal regulation between GLUT isotypes, IR 
and CD36, it is possible to hypothesise about which of the observed abnormalities could 
represent a causative aetiological feature in SCZ. The interaction between polygenic risk for 
SCZ and IR expression across clinical groups in the present study suggests that altered IR 
expression might represent an initial pathophysiological insult, at least in individuals with high 
genetic risk. This finding is supported by associations of genetic risk for SCZ with insulin 
resistance in drug-naïve patients, shared susceptibility genes between SCZ and type 2 
diabetes and a higher prevalence of type 2 diabetes in relatives of patients with SCZ20,30. Given 
that polymorphisms in the IR itself have not been reported among common genetic risk loci 
for SCZ49, it is possible that genetic loading behind this phenotype might involve multiple 
downstream genetic variants which cause decreased IR sensitivity and consequent 
upregulation of the receptor. In this respect, alterations in members of the insulin signalling 
pathway, such as previously reported changes in Akt in the brain and periphery, are 
noteworthy75,76,96,97. Decreased IR sensitivity, resulting in reduced glucose uptake by insulin-
sensitive tissues and hyperglycaemia, might in turn explain the observed downregulation of 
GLUT1. Alternatively, as the brain uses 20-50% of available glucose, depending on activity, 
downregulation of GLUT1 and reduced glucose uptake in the brain, as has been proposed for 
SCZ, might result in a physiological ‘backlog’ of blood glucose74, systemic hyperglycaemia and 
consequent upregulation of IR expression. Finally, increased expression of CD36 and resulting 
accumulation of free fatty acids within the cell could bias the expression of both IR and GLUT1, 
consistent with the concept that alterations in fatty acid homeostasis are initial events in the 
metabolic disruption preceding insulin-resistance.
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The present results also integrate parallel hypotheses of immune and metabolic dysfunction 
in SCZ. Nutrient utilization mediated by GLUT isotypes, IR and CD36 is required to maintain a 
healthy immune response both in the brain an periphery98,99, and alterations in the expression 
of these proteins might contribute to previously reported changes in immune cell reactivity, 
subset ratios and cytokine secretion profiles in SCZ40,100–102. For example, expression of GLUT1 
and GLUT4 proteins have been shown to mediate the progression of monocyte-derived 
macrophages and brain microglia towards the M1 activated proinflammatory phenotype 
fuelled by increased anaerobic glycolysis103–105. Although the simplistic representation of M1 
vs. M2 microglial polarization has recently been challenged106, it is likely that the balance of 
GLUT1 and GLUT4 expression plays a key role in defining both the spatial and temporal 
distribution of diverse microglial phenotypes in the brain. This is relevant in the case of SCZ 
as changes in microglial activation status have been postulated to mediate cognitive 
symptoms and regional changes in cortical brain volume in subsets of patients107,108. Although 
the current findings of decreased GLUT1 expression in monocytes would suggest a less 
reactive set-point for related myeloid cell types, this could be offset by a greater GLUT4 
shuttling capacity due to increased IR expression. Further studies are needed to explore the 
functional effects of potential changes in metabolic marker expression in brain microglia in 
SCZ. Conversely, altered CD36 expression in T cell subsets in the current study could 
contribute to changes in T cell differentiation, function, and survival via altered fatty acid 
metabolism. Fatty acid uptake via CD36 has been shown to play a role in T cell activation, 
proliferation and differentiation into Th1, Th2, Tregulatory (Treg) and Th17 lineages via 
engagement of peroxisome proliferator-activated receptor subtypes98. This is consistent with 
alterations in these subtype ratios, their cytokine secretion profiles and proliferation in SCZ. 
Specifically, increased Treg cells have been reported as a compensatory mechanism for 
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proinflammatory status in SCZ and are associated with fewer negatives symptoms109. 
Concurrently, abnormal Th17 activation in SCZ has been suggested to result in immune 
infiltration across the blood brain barrier110. Finally, differences in proliferation and naïve vs. 
memory T cell proportions111 or Th1 vs. Th2 cytokine secretion100 has been observed in SCZ T 
cells following antigenic stimulation. Interestingly, reports that both immune and metabolic 
alterations, for example in the glycolysis pathway proteome and cell surface metabolic 
protein expression, in SCZ are more readily observable under conditions of immune 
stimulation26 suggest that functional testing is likely necessary to fully explore the potential 
for divergent nutrient utilization in immune cells in SCZ. Likewise testing of other key 
regulators of metabolism and metabolic syndrome, such as inducible GLUT3 and GLUT4 
proteins, under conditions of antigenic stimulation might be warranted in future studies.
In addition to nutrient utilization, proteins such as CD36 also have a direct role in eliciting an 
immune response, for example by targeting activated macrophages to atherosclerotic 
plaques or recognizing bacterial and fungal pathogens65. The reverse is also true in the sense 
that immune activity is necessary for the development of metabolic syndrome. This is 
demonstrated by the absence of insulin resistance in knockout mice with mutations in SCZ-
associated49,97,112 JAK-STAT immune cell signalling pathways relative to wild-type controls113 
and links between macrophage activation status and metabolic syndrome in animal models 
of obesity110. Moreover, the fact that alterations in CD36, GLUT1 and IR in the present study 
were specific to different cell subsets suggests that different PBMC subtypes may represent 
more relevant surrogate models for different metabolic abnormalities and consequently their 
implications for immune cell function might be cell subtype-specific. In this respect, the 
relatively high expression of all three markers and enrichment of SCZ associations on 
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monocytes highlights this cell type for future investigation. Interestingly, no metabolic 
alterations were found on B cells despite intermediate expression of CD36 and IR on this cell 
type. This is notable given the enrichment of SCZ-associated risk loci in B cell subtype-specific 
gene expression enhancers in GWAS analyses49.
Finally, the current results support the concept that alterations in peripheral metabolic 
markers at disease-onset can predict subsequent response to treatment or side effects. The 
association of monocyte IR expression with changes in BPRS and SANS scores at 6 weeks and 
3 months is notable as there is an urgent need to predict response to refractory symptom 
subtypes such as negative symptoms early in the disease progression. Interestingly, CD36 
expression in monocytes which has previously been found to predict improvement in positive 
symptoms in SCZ114, was not significant, although this may relate to the small sample size 
(n=10) and the drug treatment used (olanzapine) in the previously reported cohort. The 
observed prediction of weight gain and changes in HDL using increased CD36 is consistent 
with the role of CD36 in lipid storage and lipoprotein homeostasis90. Moreover, the fact that 
CD36 is associated with weight gain early in the course of treatment, before the average onset 
of severe metabolic side effects such as type 2 diabetes and cardiovascular disease, is 
consistent with the hypothesis that CD36 is an early mediator of metabolic syndrome90. 
Nevertheless, the difficulties in obtaining antipsychotic drug-naïve patient PBMC samples 
mean that the sample numbers reported in the present study remain relatively low compared 
to the likely complexity of the phenotype. In this respect further studies are needed in larger 
drug-naïve patient cohorts with carefully controlled baseline clinical parameters, such as BMI, 
to determine the clinical utility of these markers to predict metabolic effects of 
neuropsychiatric treatment.
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These results also allow us to refine the potential implications of treatment with atypical 
antipsychotic medications. The majority of studies have focused on metabolic disturbances 
as side effects of antipsychotic treatment, including direct effects of atypical antipsychotic 
drugs at cellular and physiological levels. These include reports of increased glucose uptake 
in adipocytes115, orexigenic effects of histamine 1 antagonism in the brain116, inhibition of 
insulin signalling proteins75 and direct GLUT antagonism in the blood brain barrier93. However, 
the present results suggest that the development of metabolic syndrome over the course of 
antipsychotic therapy might represent an interaction between predisposition to metabolic 
disturbances, at least in subgroups of SCZ patients, and the effects of the drugs themselves. 
In this respect, the present results provide a prospective means to stratify patients in terms 
of metabolic risk using accessible cellular tissue. Given the variable metabolic side effect 
profile of different antipsychotics, this could potentially serve to inform the personalized 
choice of antipsychotic administered and to facilitate closer monitoring of metabolic side 
effects in at-risk individuals. This type of data could also provide rationale for recent interest 
in the use of adjunctive medications, such as glucagon-like peptide-1 agonists, to manage side 
effects of antipsychotic medication117. Finally, these findings suggest that metabolic 
parameters in SCZ may not solely be linked to side effects, but might also be related to clinical 
efficacy. While clinical trials aimed at repurposing metabolic drugs for SCZ have met with 
mixed results118, these findings suggest that further testing, combined with improved patient 
stratification, might be warranted to explore the possibility of metabolic compounds with 
efficacy in subgroups of SCZ patients.
Taken together the present findings suggest that key indicators of metabolic syndrome are 
present in PBMCs from subgroups of SCZ patients at disease onset and that these are 
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associated with both side effects and the efficacy profile of currently used medications. 
Identification of such features at disease onset could potentially facilitate improved strategies 
for the personalized management of debilitating side effects, such as an increased risk of type 
2 diabetes and cardiovascular disease, and better long-term treatment outcomes for 
individuals with SCZ.
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Figure legends
Figure 1 Differential expression of metabolic markers in peripheral blood mononuclear cell 
(PBMC) subsets across the neuropsychiatric spectrum. Shows metabolic markers and PBMC 
cell subtypes with a  significant association to clinical group status across the five comparison 
groups, autism spectrum condition (ASC; yellow), bipolar disorder (BD; red), major depressive 
disorder (MDD; blue), schizophrenia (SCZ; purple) (n=25 each) and typical controls (CTRL; 
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n=100; green) (P<0.05, ANCOVA F-test, lower P values), and additionally between at least one 
of the neuropsychiatric condition groups and controls (P<0.05, pairwise t-test of adjusted 
means, upper P values). Plots show median fluorescence intensity (MFI) of epitope expression 
(y axis) per clinical group (x axis). Only markers with a median stain index (MFI of stained/MFI 
of unstained condition) greater than two and a fold change (MFI neuropsychiatric condition 
/MFI CTRL) of minimum 5% per PBMC subtype in at least one of the clinically significant 
groups are shown. Optional covariates included age, gender, body mass index, treatment 
status and cell count. GLUT1 - glucose transporter 1 and CD36 - fatty acid translocase. 
Asterisks denote P values within the plots as follows: *P<0.05 **P<0.005 ***P<0.0005. 
Figure 2 Expression of metabolic markers in PBMC subsets in the extended schizophrenia 
cohort. Shows metabolic markers and PBMC cell subtypes which are significantly associated 
(P<0.05, ANCOVA F-test) with first-episode antipsychotic-naïve schizophrenia (SCZ; n=58) 
relative to typical controls (CTRL; n=63). Plots show median fluorescence intensity (MFI) of 
epitope expression (y axis) per clinical group (x axis). Only markers with a median stain index 
(MFI of stained/MFI of unstained condition) greater than two and a fold change (MFI 
neuropsychiatric condition /MFI CTRL) of minimum 5% per PBMC subtype in at least one of 
the clinical groups are shown. Optional covariates included age, gender, body mass index and 
cell count. GLUT1 - glucose transporter 1, IR - insulin receptor and CD36 - fatty acid 
translocase. Asterisks denote P values as follows: *P<0.05 **P<0.005 ***P<0.0005.
Figure 3 Characterization of PBMC metabolic markers associated with schizophrenia in the 
context of clinical insulin sensitivity and schizophrenia polygenic risk. Shows (a) the significant 
association (P<0.05, multivariable linear regression) of insulin receptor (IR) expression in 
monocytes (y axis) with clinical insulin sensitivity based on the updated Homeostasis Model 
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Assessment (HOMA2-%S; x axis) and (b) the significant interaction (P<0.05, multivariable 
linear regression) of insulin receptor (IR) expression in monocytes (y axis) and whole genome 
schizophrenia (SCZ) polygenic risk score (x axis) with clinical group status. Plots show marginal 
effects with 95% confidence intervals and estimates (β; calculated from scaled predictor and 
outcome values, to improve interpretability) based on values adjusted for optional covariates 
age, gender, body mass index and cell counts for first-episode antipsychotic-naïve SCZ (n=58) 
and typical control (CTRL; n=63) groups. P values represent the significance of (a) association 
for both groups combined (upper) or each group separately (lower) and (b) interaction 
between clinical groups (upper) derived from multivariable linear regression.
Figure 4 Prediction of antipsychotic efficacy and side effects using PBMC metabolic markers 
associated with schizophrenia. Prediction of changes (Δ) in clinical symptoms, measured using 
the Brief Psychiatric Rating Scale (BPRS; a,b) and the Scale for the Assessment of Negative 
Symptoms (SANS; c,d), and the side effect of weight gain, measured using body mass index 
(BMI; e), in a longitudinal follow-up of first-episode antipsychotic-naïve schizophrenia (SCZ) 
patients, treated initially with antipsychotic drugs aripiprazole (n=28) or risperidone (n=29), 
using insulin receptor (IR) expression in monocytes (a-d) and fatty acid translocase (CD36) 
expression in CD4+ T cells (e). Plots shows significant marginal effects (P<0.05, multivariable 
linear regression) with 95% confidence intervals and estimates (β; calculated from scaled 
predictor and outcome values, to improve interpretability) based on values adjusted for 
optional covariates (baseline value, age, gender, BMI, cell counts and treatment status).
Figure S1 Gating strategy for cell viability, immunophenotyping and metabolic marker 
expression across neuropsychiatric spectrum. Figure shows batched PBMC samples from 
autism spectrum condition (ASC), bipolar disorder (BD), major depressive disorder (MDD), 
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schizophrenia (SCZ) (n=25 each) and typical controls (Ctrl; n=100), in addition to replicate QC 
samples from an individual healthy donor (n=16). (a) PBMCs were gated (FSC-A vs. SSC-A), 
followed by single cell discrimination (SSC-A vs. SSC-W and FSC-A vs. FSC-W) and viability 
measurement (DAPI-A vs. SSC-A). (b) Within the live cell gate, relative proportions of T, CD3- 
(largely B and natural killer (NK) cells; labelled 'B cells') and monocytic cells were quantified 
using anti-CD3 PE-Cy7 and anti-CD14 V500. Within the T cell gate, relative proportions of 
CD4+, CD8+ and CD4-/CD8- cells were quantified using anti-CD4 PerCP-eF710 and anti-CD8 
APC-eF780. Cell counts are shown for parent gates below each dot plot and % frequencies of 
cells are shown next to gate names. (c) Within each cell subpopulation expression of 
metabolic markers was quantified using anti-glucose transporter 1 (GLUT1) FITC, anti-insulin 
receptor (IR) PE and anti-fatty acid translocase (CD36) eF660. Histograms show overlay of 
metabolic-marker stained condition (red) vs. unstained condition (blue) with cell subtypes 
and cell counts inset. 
Figure S2 Stain indexes for metabolic marker expression across the neuropsychiatric 
spectrum. Figure shows mean stain indexes (median fluorescence intensity (MFI) of 
stained/MFI of unstained condition; logarithmic y axes) for each PBMC subtype and metabolic 
marker across the clinical groups including autism spectrum condition (ASC), bipolar disorder 
(BD), major depressive disorder (MDD), schizophrenia (SCZ) (n=25 each) and typical controls 
(Ctrl; n=100). GLUT1 - glucose transporter 1, IR - insulin receptor and CD36 - fatty acid 
translocase.
Figure S3 Differences in PBMC subtype frequencies across the neuropsychiatric spectrum. 
Shows PBMC cell subtypes as a percentage of total PBMC cell counts (y axes) across the five 
comparison groups (x axes), including autism spectrum condition (ASC; yellow), bipolar 
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disorder (BD; green), major depressive disorder (MDD; blue), schizophrenia (SCZ; purple) 
(n=25 each) and typical controls (CTRL; n=100; pink). Significant associations with clinical 
status are shown for five group comparison (P<0.05, ANCOVA F-test, lower P values) and 
individual neuropsychiatric condition vs. control comparisons (P<0.05, pairwise t-test 
comparisons of adjusted means, upper P values). Optional covariates included age, gender, 
body mass index and treatment status. Asterisks denote P values within the plots as follows: 
*P<0.05 **P<0.005 ***P<0.0005.
Figure S4 Gating strategy for cell viability, immunophenotyping and metabolic marker 
expression in extended schizophrenia cohort. Figure shows batched PBMC samples from 
schizophrenia (SCZ) (n=39) and typical control (Ctrl; n=39) groups, in addition to replicate QC 
samples from an individual healthy donor (n=10). (a) PBMCs were gated (FSC-A vs. SSC-A), 
followed by single cell discrimination (SSC-A vs. SSC-W and FSC-A vs. FSC-W) and viability 
measurement (DAPI-A vs. SSC-A). (b) Within the live cell gate, relative proportions of T, CD3- 
(largely B and natural killer (NK) cells; labelled 'B cells') and monocytic cells were quantified 
using anti-CD3 PE-Cy7 and anti-CD14 V500. Within the T cell gate, relative proportions of 
CD4+, CD8+ and CD4-/CD8- cells were quantified using anti-CD4 PerCP-eF710 and anti-CD8 
APC-eF780. Cell counts are shown for parent gates below each dot plot and % frequencies of 
cells are shown next to gate names. (c) Within each cell subpopulation expression of 
metabolic markers was quantified using anti-glucose transporter 1 (GLUT1) FITC, anti-insulin 
receptor (IR) PE and anti-fatty acid translocase (CD36) eF660. Histograms show overlay of 
metabolic-marker stained condition (orange) vs. unstained condition (blue) with cell subtypes 
and cell counts inset. 
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Figure S5 Stain indexes for metabolic marker expression in extended schizophrenia cohort. 
Figure shows mean stain indexes (median fluorescence intensity (MFI) of stained/MFI of 
unstained condition; logarithmic y axes) for each PBMC subtype and metabolic marker in 
schizophrenia (SCZ) (n=39) and typical control (CTRL; n=39) groups. GLUT1 - glucose 
transporter 1, IR - insulin receptor and CD36 - fatty acid translocase.
Figure S6 Longitudinal (0 weeks - 3years; x axes) clinical assessment (y axes) of body mass 
index (BMI; a), serum metabolic parameters (b-g) and schizophrenia (SCZ) symptoms, 
measured using the Brief Psychiatric Rating Scale (BPRS; h), the Scale for the Assessment of 
Positive Symptoms (SAPS; i), the Scale for the Assessment of Negative Symptoms (SANS; j), in 
first-episode antipsychotic-naïve SCZ patients treated with antipsychotic drugs aripiprazole 
(n=28; red) or risperidone (n=29; blue). 0 weeks represents antipsychotic drug-naïve time 
point. Patients are colour-coded with respect to the drug administered at baseline. Black lines 
connect time point means and error bars represent standard error of the mean. HDL - high-
density lipoprotein, LDL - low-density lipoprotein, m – month, TG -triglycerides, w – week, y – 
year.
Table S1 Demographic characteristics and matching of PBMC samples across the 
neuropsychiatric spectrum. Matching was achieved between typical control (CTRL, combined 
four cohorts of 25 controls, n=100), autism spectrum condition (ASC, n=25), bipolar disorder 
(BD, n=25), major depressive disorder (MDD, n=25) and schizophrenia (SCZ, n=25) clinical 
groups for all variables except higher age in the MDD group relative to the CTRL, ASC and SCZ 
groups and higher body mass index (BMI) in the MDD group relative to the SCZ group. Table 
shows mean values ± standard deviation, statistic and P value from Kruskal-Wallis test (for 
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continuous variables) or chi-squared test (for categorical variable) and significant pairwise 
comparisons from post-hoc Dunn’s test. Asterisk (*) denotes data missing for 2 patients.
Table S2 Within-cohort matching of individual patient groups (n=25) and respective controls 
(CTRL; n=25 per cohort) across the neuropsychiatric spectrum. Matching was achieved for all 
cohorts (autism spectrum condition (ASC), bipolar disorder (BD), major depressive disorder 
(MDD) and schizophrenia (SCZ)) and demographic variables (P≥0.05). Statistical tests included 
Wilcoxon rank-sum test for continuous variables and Fisher’s exact test for the categorical 
variable. Table shows mean values ± standard deviation. BMI – body mass index. Asterisk (*) 
denotes data missing for 2 patients.
Table S3 Alterations in the expression of metabolic markers across the neuropsychiatric 
spectrum. Table shows association of metabolic marker expression (Readout) in each PBMC 
subtype (Cell subtype) with clinical group status across the neuropsychiatric spectrum before 
(ANOVA.P) and after (ANCOVA.P) adjusting for covariates selected using Bayesian Information 
Criterion. Final model selection for ANCOVA tests is shown in Model column. ANCOVA.P 
values adjusted for multiple comparisons using the Benjamini-Hochberg procedure are shown 
as ANCOVA.Q. Pairwise t-test comparisons P(>t) of adjusted group means indicate clinical 
groups which differed significantly (P<0.05) from typical controls, in addition to respective 
disease/control fold changes (FC).  Sample numbers (N) are shown for each clinical group and 
test respectively. Only metabolic markers with a median stain index greater than two in at 
least one of the comparison groups were used for analysis. Clinical groups are abbreviated as 
follows: typical controls (CTRL), autism spectrum condition (ASC), bipolar disorder (BD), major 
depressive disorder (MDD) and schizophrenia (SCZ). Terms in italics refer to column headings.
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Table S4 Demographic and clinical data of patients with schizophrenia (SCZ) and unaffected 
controls (CTRL) in the extended schizophrenia (ES) cohort. Shows mean and standard 
deviation (SD) for continuous variables, and numbers (N) and percentages for categorical 
variables. P values were obtained using t-test for continuous variables and Fisher’s or chi-
squared test for categorical variables. P<0.05 was considered significant. Column ‘Missing (N)’ 
shows the number of missing values for each parameter per clinical group. Abbreviations: - 
(hyphen) - not applicable, %B - beta cell function (%), BMI - body mass index, BPRS - Brief 
Psychiatric Rating Scale, HDL - high-density lipoprotein, HOMA2 - the updated Homeostasis 
Model Assessment, IR - insulin resistance, LDL - low-density lipoprotein, PRS – whole-genome 
schizophrenia polygenic risk score, SANS - Scale for the Assessment of Negative Symptoms, 
SAPS - Scale for the Assessment of Positive Symptoms, %S - insulin sensitivity (%). * P <0.05, 
** P<0.01, *** P<0.001.
Table S5 Alterations in the expression of metabolic markers in the extended schizophrenia 
cohort. Table shows association of metabolic marker expression (Readout) in each PBMC 
subtype (Cell subtype) with schizophrenia before (ANOVA.P) and after (ANCOVA.P) adjusting 
for covariates selected using Bayesian Information Criterion. Final model selection for 
ANCOVA tests is shown in Model column. ANCOVA.P values adjusted for multiple 
comparisons using the Benjamini-Hochberg procedure are shown as ANCOVA.Q. Respective 
disease/control fold changes are shown as FC.  Sample numbers (N) are shown for each clinical 
group and test respectively. Only metabolic markers with a median stain index greater than 
two in at least one of the comparison groups were used for analysis. Clinical groups are 
abbreviated as follows: typical controls (CTRL) and schizophrenia (SCZ). Terms in italics refer 
to column headings.
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Table S6 Associations of metabolic markers, significantly linked to schizophrenia (SCZ) in the 
extended SCZ (ES) cohort, with Homeostasis Model Assessment (HOMA-2) metrics. Table 
shows association of metabolic marker expression (Readout) in each PBMC subtype (Cell 
subtype) and clinical group (Group) with insulin sensitivity (HOMA2.S), insulin resistance 
(HOMA2.IR) and pancreatic -cell function (HOMA2.B) before (ANOVA.P) and after 
(ANCOVA.P) adjusting for covariates selected using Bayesian Information Criterion. Final 
model selection for ANCOVA tests is shown in Model column along with the Estimate and 
Standard Error. ANCOVA.P values adjusted for multiple comparisons using the Benjamini-
Hochberg procedure are shown as ANCOVA.Q. Sample numbers (N) are shown for each 
clinical group and test respectively. Terms in italics refer to column headings. Clinical groups 
are abbreviated as follows: typical controls (CTRL) and schizophrenia (SCZ). Terms in italics 
refer to column headings.
Table S7 Associations of metabolic markers, significantly linked to schizophrenia (SCZ) in the 
extended SCZ (ES) cohort, with whole-genome polygenic risk of SCZ. Table shows association 
of metabolic marker expression (Readout) in each PBMC subtype (Cell subtype) with polygenic 
risk of SCZ (PRS) across clinical groups before (ANOVA.P) and after (ANCOVA.P) adjusting for 
covariates selected using Bayesian Information Criterion. Interaction.P shows interactions 
between clinical group status and the relationship of SCZ polygenic risk score with metabolic 
marker expression, determined prior to fitting main effect model shown. Final main effect 
model selection for ANCOVA tests is shown in Model column along with the Estimate and 
Standard Error. Interaction.P values adjusted for multiple comparisons using the Benjamini-
Hochberg procedure are shown as Interaction.Q. Sample numbers (N) are shown for each 
clinical group and test respectively. Terms in italics refer to column headings. Clinical groups 
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are abbreviated as follows: typical controls (CTRL) and schizophrenia (SCZ). Terms in italics 
refer to column headings.
Table S8 Prediction of antipsychotic efficacy and side effects using PBMC metabolic markers 
associated with schizophrenia (SCZ). Shows Prediction of changes (d.) in clinical symptoms, 
measured using the Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of 
Positive Symptoms (SAPS) and the Scale for the Assessment of Negative Symptoms (SANS) at 
6 weeks (6w) and 3 months (3m), and the side effect of weight gain, measured using changes 
in body mass index (BMI) at 3m, in a longitudinal follow-up of SCZ patients in the ES cohort. 
Predictions are based on metabolic marker expression (Readout) in PBMC subtypes (Cell 
subtype) which were significantly linked to SCZ. Patients were treated initially with 
antipsychotic drugs aripiprazole (n=28) or risperidone (n=29). Association results before 
(ANOVA.P) and after (ANCOVA.P) adjusting for covariates selected using Bayesian Information 
Criterion are shown. Final model selection for ANCOVA tests is shown in Model column along 
with the Estimate and Standard Error. ANCOVA.P values adjusted for multiple comparisons 
using the Benjamini-Hochberg procedure are shown as ANCOVA.Q. Sample numbers (N) are 
shown for each test respectively. Terms in italics refer to column headings.
Descargado para Anonymous User (n/a) en IDIVAL, de ClinicalKey.es por Elsevier en septiembre 10, 2020.
Para uso personal exclusivamente. No se permiten otros usos sin autorización. Copyright ©2020. Elsevier Inc. Todos los derechos reservados.
